Lenvatinib in Advanced Hepatocellular Carcinoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis.Internal and emergency medicine · 2021
   Pooled it
2. Efficacy of Second-Line Lenvatinib After Atezolizumab-Bevacizumab and Durvalumab-Tremelimumab in Unresectable Hepatocellular Carcinoma: Association with Prior Immunotherapy Response.Cancers · 2026
   Article
3. Identification and validation of a lenvatinib resistance-related prognostic signature in HCC, in which PFKFB4 contributes to tumor progression and lenvatinib resistance.BMC gastroenterology · 2025
   Article
4. Immunotherapy for advanced or recurrent hepatocellular carcinoma.World journal of gastrointestinal oncology · 2023
   Review
5. The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma.Frontiers in immunology · 2023
   Article
6. Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities.Cancers · 2022
   Review
7. The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma.Journal of clinical medicine · 2022
   Article
8. Hybrid Lipid Nanoformulations for Hepatoma Therapy: Sorafenib Loaded Nanoliposomes-A Preliminary Study.Nanomaterials (Basel, Switzerland) · 2022
   Article
9. Genetic Landscape of Multistep Hepatocarcinogenesis.Cancers · 2022
   Review
10. Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook.Journal of hepatocellular carcinoma · 2022
    Review
11. Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment.Pharmaceutics · 2021
    Review
12. Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma.World journal of gastrointestinal oncology · 2021
    Review
13. From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis.International journal of molecular sciences · 2021
    Review
14. Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma.Frontiers in immunology · 2021
    Review
15. Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway.BioMed research international · 2021
    Article
16. Olaparib combined with immunotherapy for treating a patient with liver cancer carrying BRCA2 germline mutation: A case report.Medicine · 2020
    Article
17. Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies.Hepatic oncology · 2020
    Review
18. RGFP966 Suppresses Tumor Growth and Migration Through Inhibition of EGFR Expression in Hepatocellular Carcinoma Cells in vitro.Drug design, development and therapy · 2020
    Article
19. Intravenous Injections of a Rationally Selected Oncolytic Herpes Virus as a Potent Virotherapy for Hepatocellular Carcinoma.Molecular therapy oncolytics · 2019
    Article
20. Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion.Molecular and clinical oncology · 2019
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.